ArcticZymes Technologies (AZT)

Taxidriver · januar 30, 2019, 9:09am

Woulgan har solgt for 900kNOK i Q4. Det er omtrent ingen ting.
Har selv testet Woulgan på et vanskelig sår på en bekjent. Såret hadde diameter på ca 10 cm og hadde ikke grodd på 8 måneder. Med Woulgan lukket såret seg på ca 8 uker. Vedkommende var selvsagt superfornøyd og jeg klarer ikke å fatte at det ikke er større behov for produktet. Hvorfor er det så lite interesse for å bruke Woulgan blant fagfolk? Har de produkter som er bedre?

FiloD · januar 30, 2019, 9:21am

Konservative kunder og ekstrem sterk konkurrence er nok svaret på dine spørgsmål. Jeg er ganske sikker på at de ikke har bedre produkter, men dette vil kreve mye arbeid og ta lang tid.

BioMed · januar 30, 2019, 10:29am

Siste handler
Klokka Pris Volum Kjøper Selger

10:36:00 4.20 …319 502

TekBot · februar 4, 2019, 4:06pm

03/02-2019 22:31:13: (BIOTEC) Financial calendar

TekBot · februar 4, 2019, 4:06pm

04/02-2019 07:59:00: (BIOTEC) Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product

The grant has been awarded from the User-driven Research-based Innovation Programme (BIA), and the focus of the project will be to develop first of its kind bioactive gel-forming fibre dressings. These dressings will contain soluble beta-glucan (SBG®) for the treatment of hard-to-heal wounds by re-activating the healing process.

The project aims to develop new and cost-effective wound healing devices for the treatment of large hard-to-heal wounds, exuding wounds (burns and ulcers), donor-site wounds, and wounds on mucosal surfaces.
…

Vis børsmeldingen

Established in 2006, the BIA programme is one of the largest programmes at the Research Council and is a key partner for Norwegian trade and industry. This broad-based programme supports high-quality R&D projects with good business and socio-economic potential.

The award is subject to successful contract negotiations between the parties.

Christian Jørgensen, CEO, said:

“We are pleased to have been awarded this grant, which serves as a great testament to the hard work being done at Biotec BetaGlucans. It will help us develop a broader set of treatments for the many people suffering from different types of hard-to-heal wounds.”

-ENDS-

For more information, please contact:

Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: [email protected]
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah [email protected]
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.

http://www.netfonds.no/quotes/release.php?id=20190204.Cision.20190203:BIT:8616:0

TekBot · februar 7, 2019, 1:43pm

07/02-2019 14:41:12: (BIOTEC) Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme

T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research market segments.

This launch represents the Company’s first non-novel enzyme in its expanding portfolio and fulfils customer requests for such enzymes. The high-quality and commercial grade ligase is produced under the strict ISO 13485 guidelines. It fits synergistically in the Company’s portfolio and can be used by customers either in combination with their own enzymes or alongside ArcticZymes novel enzymes.
…

Vis børsmeldingen

ArcticZymes has several other ligase products in development. Numerous prototypes of novel ligases are currently with leading commercial customers for early access evaluations. Customer feedback from these evaluations will then steer the Company’s plans to commercialise further ligases in 2019.

Jethro Holter, Managing Director ArcticZymes said:

"The launch of the T4 DNA ligase fits with our strategy to expand our current portfolio beyond novel enzyme products. Our goal is to continue to leverage our experience to grow a synergistic portfolio through organic and non-organic growth initiatives.

“As a trusted component supplier to the industry we are transitioning the business towards becoming the leading one-stop shop for molecular biology enzymes.”

ENDS -

For more information, please contact:

Biotec Pharmacon
Christian Jørgensen, CEODr Tel: +47 47 79 24 57
Jethro Holter, MD ArcticZymes Tel: +47 46 85 91 46
Email: [email protected]

Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan /Deborah [email protected]
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About ArcticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.

Some of its enzymes’ unique features include heat lability and activity in challenging environments as well as customised, engineered novel features which can be integrated to power the technologies of commercial partners.

All ArcticZymes products are ISO certified.

For more information, please visit: www.arcticzymes.com

http://www.netfonds.no/quotes/release.php?id=20190207.Cision.20190207:BIT:2457:0

FiloD · februar 7, 2019, 1:59pm

Noen som vet hvem som solgte og kjøpte?

TekBot · februar 18, 2019, 6:57am

18/02-2019 07:55:12: (BIOTEC) Biotec Pharmacon - Mandatory notification of trade

BioMed · februar 22, 2019, 3:51pm

Bra oppgang idag +8%

BioMed · februar 22, 2019, 8:30pm

Hei @FiloD,

Hvordan tolker du dette ?

ArcticZymes, a Biotec Pharmacon subsidiary, has released a T4 DNA ligase, its first commercial ligase enzyme. T4 DNA ligase is the most widely used enzyme in the ligase family, and works by joining DNA fragments together. It is used in the development of kits and products for in vitro diagnostics and molecular research. The ligase is produced under strict ISO 13485 guidelines, and can be used by customers either in combination with their own enzymes or alongside other ArcticZymes enzymes.

FiloD · februar 23, 2019, 7:06am

Dette syntes jeg er veldig gode nyheter for Biotec Pharmacon. Endelig går de inn i et litt større enzym område som kan få mere fatt på omsætningen for AZ. Og marginerne er jo hinsides.

Holter gjør en veldig god jobb, og som jeg forstår så har Jørgensen vært ganske hård med sparekniven, så de begynner å få snudd skuta.

Jeg tror ikke at en indgang på disse niveauer vil være så dårlig. men det tar fortsatt tid før det ta’r fyr.

Kronn · februar 23, 2019, 7:27am

Synd det er dårlig omsetning i aksjen, mengden kommer seg vek etterhvert som selskapet leverer.

Kronn · februar 23, 2019, 7:43am

Hva tenker dere angående woulgan, vil den noen gang bli noe mer enn det den har vert til nå ?

BioMed · februar 23, 2019, 2:32pm

Takk for svar Filo. Tok noen lodd her , kan bli bra på sikt . De som sitter i aksjen tror jeg ikke bør selge nå .

Adjuvant study with MSKCC in New York

•A new clinical trial agreement was signed during Q4 2018 securing rights
for possible inventions from the study being carried out

•Study is now developed into a two-arm study, to isolate and document the
effect of our SBG® (260 pasienter)

SBG® is currently used as adjuvant in immunotherapy of cancer to strengthen the efficacy of an anti-GD2 neuroblastoma vaccine (NCT00911560) ongoing at Memorial Sloan Kettering Cancer Centre, NY, USA. The product has earlier been employed in clinical trials to potentiate cancer antibodies both in US and Norway (NCT00492167; NCT00533364; NCT00533728). SBG®, being a conserved pathogen associated molecular pattern (PAMP), has the ability to potentiate the effector mechanisms of white blood cells (e.g. macrophages and neutrophils) when recognising anti-body labelled cancer cells. The beta-glucan product would also enhance the immune response to antigens improving both the humoral and cellular immunity towards vaccines. A possible effect of beta-glucan on the tumor microenvironment (TME) has also been highlighted as a promising tool for improving immunetherapeutic strategies (Zhang et al. 2018, Frontiers in Immunology 9:341).

BioMed · mars 5, 2019, 7:06pm

Blir interessant å følge fremover. Last Update Posted : February 28, 2019

https://www.mskcc.org/cancer-care/clinical-trials/05-075?fbclid=IwAR3Z8HS7MGwum_INgQwWWjnbE6bbqeIunf32Z76W1rNihAdNcHcGpzrtU_Y

https://biotec.no/news/biotec-renews-clinical-trial-agreement-with-memorial-sloan-kettering-cancer-center/

TekBot · april 2, 2019, 9:36am

02/04-2019 11:35:11: (BIOTEC) Biotec Pharmacon’s subsidiary, ArcticZymes, granted €254.000 funding from Eurostars for a synthetic biology project

The project proposal was developed in collaboration with the University of Tromsø and Danish company, Legomics, has been positively evaluated by the Eurostars programme. ArcticZymes is to participate in developing novel DNA ligases, enabling novel chemistry for synthetizing DNA and genes to be further developed by Legomics.

Working alongside the University of Tromsø, ArcticZymes have used Arctic marine bioprospecting and engineering to establish a substantial base for the development of enzymes with novel unique properties.
…

Vis børsmeldingen

ArcticZymes Managing Director Jethro Holter said:

“This project supports ArcticZymes ambitions towards building a broader synergistic product portfolio, with wide applicability across all three molecular biology market segments it serves - research, IVD and therapeutics. We are also excited to partner with Legomics and the University of Tromsø in enabling a novel gene synthesis technology.”

Christian Jørgensen, CEO, added:

“The project will further strengthen our long-term collaboration with the University of Tromsø in the discovery of other classes of unique enzymes. Furthermore, we are looking forward to establishing a closer relationship with Legomics and developing enzyme technology for use in gene synthesis technology and various other applications.”

-ENDS-

For more information, please contact:

Biotec Pharmacon
Christian Jørgensen, CEO                                           Tel: +47 47 79 24 57
Dr Jethro Holter, MD ArcticZymes                               Tel: + 47 46 85 91 46
                                                                                    Email: [email protected]

Instinctif Partners
Melanie Toyne-Sewell / Dr Christelle Kerouedan /       Tel: +44 207 457 2020
Deborah Bell                                                                [email protected]

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high-tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About ArticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth markets where rapid technological developments are creating a strong demand for new and improved enzymes. Some of its enzymes’ unique features include heat lability and activity in challenging environments as well as customised, engineered novel features which can be integrated to power the technologies of commercial partners.

All ArcticZymes products are ISO certified.

For more information, please visit: www.arcticzymes.com

About University of Tromsø

UiT The Arctic University of Norway (https://en.uit.no/startsida) is the world’s northernmost University which is reflected in the strong innovation focus of its research activities, often drawing on this unique geographical location. The department of Chemistry has a strong profile in cold-active enzyme discovery and engineering for biotechnological purposes. This is facilitated by superb access to sampling locations in Arctic regions, in-house competence regarding biomining of (meta)genomic data and cutting-edge structural biology infrastructure through the national NorCryst platform. The translation of fundamental scientific findings to commercial solutions is enabled by collaboration with industrial partners and participation in innovation-focused projects at national and international levels.

About Legomics

Legomics is a Danish company and spin-off of Genomic Expression. Legomics technology enables the development of a desktop gene writer using enzymes.

Other chemistries for DNA synthesis are based on harsh organic chemicals and bulky pipetting robots for the assembly of all the fragments. It is a tedious and time-consuming process because smaller custom-made pieces of DNA have to be assembled by hand or with a pipetting robot giving a lead time of 2-4 weeks to get a new piece of DNA comprising one or more genes. By an enzymatic driven process, Legomics aims to develop the technology for a desktop gene writer that would increase speed and lower the cost of DNA- and gene synthesis, democratizing the process and fueling new innovations.

About Eurostars

Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (https://www.eurostars-eureka.eu/eurostars-faq) (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world. Eurostars has been carefully developed to meet the specific needs of SMEs. It is an ideal first step in international cooperation, enabling small businesses to combine and share expertise and benefit from working beyond national borders.

Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries (https://www.eurostars-eureka.eu/eurostars-faq) and by the European Union through Horizon 2020. In the 2014-2020 period it has a total public budget of €1.14 billion.

For more information, please visit www.eurostars-eureka.eu

http://www.netfonds.no/quotes/release.php?id=20190402.Cision.20190402:BIT:6894:0

TekBot · april 2, 2019, 9:36am

02/04-2019 11:35:29: (BIOTEC) Biotec Pharmacon’s subsidiary, ArcticZymes, granted ?254.000 funding from Eurostars for a synthetic biology project

Tromsø, Norway, 2. April 2019 - Biotec Pharmacon (OSE: Biotec) announced today
that its subsidiary, ArcticZymes, has been granted Euro 254k as part of a
collaborative project on the development of novel enzymes for synthetic
…
Vis børsmeldingen

biology.
The project proposal was developed in collaboration with the University of
Tromsø and Danish company, Legomics, has been positively evaluated by the
Eurostars programme. ArcticZymes is to participate in developing novel DNA
ligases, enabling novel chemistry for synthetizing DNA and genes to be further
developed by Legomics.

Working alongside the University of Tromsø, ArcticZymes have used Arctic marine
bioprospecting and engineering to establish a substantial base for the
development of enzymes with novel unique properties.

ArcticZymes Managing Director Jethro Holter said:

“This project supports ArcticZymes ambitions towards building a broader
synergistic product portfolio, with wide applicability across all three
molecular biology market segments it serves - research, IVD and therapeutics. We
are also excited to partner with Legomics and the University of Tromsø in
enabling a novel gene synthesis technology.”

Christian Jørgensen, CEO, added:

“The project will further strengthen our long-term collaboration with the
University of Tromsø in the discovery of other classes of unique enzymes.
Furthermore, we are looking forward to establishing a closer relationship with
Legomics and developing enzyme technology for use in gene synthesis technology
and various other applications.”

-ENDS-

For more information, please contact:

Biotec Pharmacon
Christian Jørgensen, CEO Tel: +47 47
79 24 57
Dr Jethro Holter, MD ArcticZymes Tel: + 47 46 85
91 46
Email: [email protected]
Instinctif Partners
Melanie Toyne-Sewell / Dr Christelle Kerouedan / Tel: +44 207 457 2020
Deborah Bell
[email protected]

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsoe to offer niche and high-tech products in
several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About ArticZymes

ArcticZymes develops, produces and markets novel recombinant enzymes for use in
molecular research, In Vitro Diagnostics (IVD) and therapeutics.

The Company focuses on novel and high-quality enzyme technologies in growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes. Some of its enzymes’ unique features include heat
lability and activity in challenging environments as well as customised,
engineered novel features which can be integrated to power the technologies of
commercial partners.

All ArcticZymes products are ISO certified.

For more information, please visit: www.arcticzymes.com

About University of Tromsø

UiT The Arctic University of Norway (https://en.uit.no/startsida) is the world’s
northernmost University which is reflected in the strong innovation focus of its
research activities, often drawing on this unique geographical location. The
department of Chemistry has a strong profile in cold-active enzyme discovery and
engineering for biotechnological purposes. This is facilitated by superb access
to sampling locations in Arctic regions, in-house competence regarding biomining
of (meta)genomic data and cutting-edge structural biology infrastructure through
the national NorCryst platform. The translation of fundamental scientific
findings to commercial solutions is enabled by collaboration with industrial
partners and participation in innovation-focused projects at national and
international levels.

About Legomics

Legomics is a Danish company and spin-off of Genomic Expression. Legomics
technology enables the development of a desktop gene writer using enzymes.

Other chemistries for DNA synthesis are based on harsh organic chemicals and
bulky pipetting robots for the assembly of all the fragments. It is a tedious
and time-consuming process because smaller custom-made pieces of DNA have to be
assembled by hand or with a pipetting robot giving a lead time of 2-4 weeks to
get a new piece of DNA comprising one or more genes. By an enzymatic driven
process, Legomics aims to develop the technology for a desktop gene writer that
would increase speed and lower the cost of DNA- and gene synthesis,
democratizing the process and fueling new innovations.

About Eurostars

Eurostars supports international innovative projects led by research and
development- performing small- and medium-sized
enterprises (https://www.eurostars-eureka.eu/eurostars-faq) (R&D-performing
SMEs). With its bottom-up approach, Eurostars supports the development of
rapidly marketable innovative products, processes and services that help improve
the daily lives of people around the world. Eurostars has been carefully
developed to meet the specific needs of SMEs. It is an ideal first step in
international cooperation, enabling small businesses to combine and share
expertise and benefit from working beyond national borders.

Eurostars is a joint programme between EUREKA and the European Commission, co
-funded from the national budgets of 36 Eurostars Participating States and
Partner Countries (https://www.eurostars-eureka.eu/eurostars-faq) and by the
European Union through Horizon 2020. In the 2014-2020 period it has a total
public budget of Euro 1.14 billion.

For more information, please visit www.eurostars-eureka.eu

http://www.netfonds.no/quotes/release.php?id=20190402.OBI.20190402S26

TekBot · april 4, 2019, 5:49pm

04/04-2019 19:47:47: (BIOTEC) Biotec Pharmacon renews contract with largest customer within Animal Health business

The Company will continue to supply and assist its long-standing customer, a major player in the Animal Health sector. Expected revenues, depending on the sales of the customer to its end-users, are approximately NOK 20m annually.

Using beta-glucans to safely and effectively enhance the immune system of farmed animals has been a core activity for Biotec Pharmacon for 30 years. The M-Glucan® product has a variety of applications to improve animals’ resistance to disease and to strengthen their growth rate. Biotec Pharmacon’s beta-glucan product is well-documented in the animal feed industry. It is supported by over 60 publications and numerous animal trials - including fish and a variety of mammals - verifying its safety and mechanism of action.
…

Vis børsmeldingen

Christian Jørgensen, CEO, said:

“We are proud to continue our long-term business relationship with this highly respected supplier of animal feed. It confirms not only the quality of our products, but also that our organization can operate and compete at the highest level in this sector.”

“This renewed contract has secured a steady revenue stream for Biotec going forward.”

ENDS -

For more information, please contact:

Biotec Pharmacon
Christian Jørgensen, CEO Tel: +47 47 79 24 57
Email: [email protected]

Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah Email: [email protected]
Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.

http://www.netfonds.no/quotes/release.php?id=20190404.Cision.20190404:BIT:9801:0

BioMed · april 4, 2019, 6:00pm

Ca. 20 millioner kroner årlig.

TekBot · april 12, 2019, 10:00am